William Blair Weighs in on Repligen Co.’s Q4 2024 Earnings (NASDAQ:RGEN)

Repligen Co. (NASDAQ:RGEN) – Investment analysts at William Blair raised their Q4 2024 earnings estimates for Repligen in a research note issued on Tuesday, July 30th. William Blair analyst M. Larew now anticipates that the biotechnology company will post earnings of $0.50 per share for the quarter, up from their previous estimate of $0.47. The consensus estimate for Repligen’s current full-year earnings is $1.44 per share.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.33 EPS for the quarter, meeting the consensus estimate of $0.33. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The company had revenue of $154.07 million during the quarter, compared to analysts’ expectations of $154.11 million. During the same quarter in the previous year, the company earned $0.53 earnings per share. Repligen’s revenue for the quarter was down 3.2% on a year-over-year basis.

RGEN has been the subject of a number of other research reports. JPMorgan Chase & Co. boosted their price target on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research note on Wednesday. Guggenheim began coverage on shares of Repligen in a research note on Tuesday, June 18th. They issued a “neutral” rating for the company. Royal Bank of Canada reissued an “outperform” rating and issued a $190.00 price target on shares of Repligen in a research note on Wednesday. Stephens reissued an “overweight” rating and issued a $170.00 price target on shares of Repligen in a research note on Tuesday. Finally, UBS Group lowered their price objective on shares of Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a report on Wednesday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $190.88.

Repligen Price Performance

RGEN stock opened at $161.67 on Thursday. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.35 and a quick ratio of 5.24. Repligen has a one year low of $110.45 and a one year high of $211.13. The stock has a market cap of $9.06 billion, a PE ratio of 646.71, a P/E/G ratio of 5.65 and a beta of 0.95. The firm has a 50 day simple moving average of $134.92 and a two-hundred day simple moving average of $166.05.

Insiders Place Their Bets

In other Repligen news, VP Ralf Kuriyel sold 4,465 shares of the stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $165.67, for a total transaction of $739,716.55. Following the completion of the sale, the vice president now directly owns 19,261 shares of the company’s stock, valued at approximately $3,190,969.87. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, CEO Anthony Hunt sold 20,072 shares of the firm’s stock in a transaction on Tuesday, May 21st. The shares were sold at an average price of $168.26, for a total value of $3,377,314.72. Following the completion of the transaction, the chief executive officer now directly owns 163,177 shares of the company’s stock, valued at $27,456,162.02. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Ralf Kuriyel sold 4,465 shares of the firm’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $165.67, for a total transaction of $739,716.55. Following the completion of the transaction, the vice president now directly owns 19,261 shares of the company’s stock, valued at $3,190,969.87. The disclosure for this sale can be found here. 1.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of RGEN. YHB Investment Advisors Inc. purchased a new position in Repligen during the first quarter worth $26,000. International Assets Investment Management LLC purchased a new position in Repligen during the second quarter worth $33,000. Lazard Asset Management LLC boosted its stake in Repligen by 206.1% during the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after buying an additional 136 shares during the period. Benjamin F. Edwards & Company Inc. boosted its stake in Repligen by 152.1% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock worth $43,000 after buying an additional 146 shares during the period. Finally, Principal Securities Inc. bought a new stake in shares of Repligen during the fourth quarter worth $48,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.